1	Immunogenicity and safety of DS-5670d, an mRNA-based
2	COVID-19 vaccine targeting omicron XBB.1.5: Results from a
3	phase 3, randomized, active-controlled study in adults and
4	children aged ≥12 years
5	
6	Ami Kawamoto ¹ , Masahiro Hashida ¹ , Katsuyasu Ishida ¹ , Kei Furihata ² , Aisaku Ota ² , Kaori
7	Takahashi ¹ , Sachiko Sakakibara ¹ , Takashi Nakano ³ , Fumihiko Takeshita ¹
8	
9	1 R&D Division, Daiichi Sankyo Co., Ltd., Tokyo, Japan
10	2 Global DX, Daiichi Sankyo Co., Ltd., Tokyo, Japan
11	3 Department of Pediatrics, Kawasaki Medical School, Okayama, Japan
12	
13	Corresponding author
14	Fumihiko Takeshita
15	1-16-13, Kitakasai, Edogawa-ku, Tokyo 134-0081, Japan
16	Tel: +81-3-3680-0151
17	Fax: +81-3-5696-7346
18	E-mail: fumihiko.takeshita@daiichisankyo.com
19	
20	Short title: DS-5670d omicron XBB.1.5 COVID-19 vaccine immunogenicity and safety
21	

It is made available under a CC-BY 4.0 International license .

22 Abstract

23 Background

24 Many people worldwide have now acquired immune responses against the severe acute

- 25 respiratory syndrome-coronavirus-2 (SARS-CoV-2) following previous vaccination and/or
- 26 infection. As a result, national vaccination programs are now implementing a simplified schedule
- 27 of single-dose administration and seasonal boosters. In this phase 3 non-inferiority study, we
- assessed the immunogenicity and safety of a single dose of the lipid nanoparticle-messenger
- ribonucleic acid vaccine DS-5670d, a monovalent composition for the 2023/24 season,
- 30 containing an omicron XBB.1.5-derived antigen.

31 Methods and Findings

32 Adults and children aged ≥12 years were stratified according to their history of both prior SARS-

33 CoV-2 infection plus prior coronavirus disease 2019 (COVID-19) vaccination (subpopulation A),

34 prior infection only (subpopulation B), prior vaccination only (subpopulation C), or no history of

35 either infection or vaccination (subpopulation D), and randomly assigned (1:1) to receive DS-

36 5670d or monovalent BNT162b2 omicron XBB.1.5. In the combined ABC subpopulations (DS-

37 5670d, n = 362 vs BNT162b2, n = 363), the adjusted geometric mean titer ratio of blood

38 neutralizing activity against SARS-CoV-2 (omicron XBB.1.5) was 1.218 (95% confidence

interval [CI], 1.059, 1.401) and the seroresponse rates were 87.3% (DS-5670d) and 82.9%

40 (BNT162b2) with an adjusted difference of 4.5% (95% CI, -0.70, 9.71). Both results exceeded

41 prespecified non-inferiority margins and the study met the primary endpoint. Immunogenicity

42 data in the overall ABCD population also met non-inferiority criteria. There were no apparent

43 differences in immunogenicity according to age or sex, and analyses suggested that even

44 unvaccinated persons achieved an adequate immune response following a single dose of DS-

45 5670d. There were no major differences in the incidence or severity of adverse events between

the study vaccination groups.

It is made available under a CC-BY 4.0 International license .

47 Conclusions

- 48 A single dose of DS-5670d was immunogenically non-inferior to BNT162b2 and acceptably safe
- 49 in persons with or without a history of prior infection and/or vaccination.
- 50 Trial Registration
- 51 Japan Registry of Clinical Trials (jRCT2031230424)

52

- 53 Key Words: COVID-19, DS-5670d, immunogenicity, non-inferiority, Omicron XBB.1.5,
- 54 SARS-CoV-2

55

- 56 Abbreviations: AE, adverse event; COVID-19, coronavirus disease 2019; CI, confidence
- 57 interval; GMT, geometric mean titer; LNP, lipid nanoparticle; mRNA, messenger ribonucleic
- acid; PPS, per protocol set; SAE, serious adverse event; SARS-CoV-2, severe acute respiratory
- 59 syndrome-coronavirus-2; SD, standard deviation.

60

61 Author summary

62 Why was this study done?

• The global emergency response against the coronavirus disease 2019 (COVID-19)

64 pandemic is now being superseded by annual immunization using an updated vaccine

- 65 composition to reduce the disease burden associated with newly emerging variants.
- We conducted a comparative study of two newly authorized updated vaccine
- 67 compositions containing the antigen derived from omicron XBB.1.5, which was
- 68 recommended for the 2023/24 season.
- We intended to assess the immunogenicity and safety of a single dose of DS-5670d
 compared with BNT162b2 in Japanese adults and children aged ≥12 years.

It is made available under a CC-BY 4.0 International license .

71 What did the researchers do and find?

72	•	In persons who had received prior vaccination, or who had previously had COVID-19, or
73		both, DS-5670d was non-inferior to BNT162b2 in terms of blood neutralizing activity and
74		seroresponse rates, and immune responses were not influenced by age or sex.
75	•	Among unvaccinated persons, those who had been exposed to SARS-CoV-2 by prior
76		infection achieved an adequate immune response following a single dose of DS-5670d;
77		however, the group who had had no previous exposure at all was too small to properly
78		evaluate.
79	•	There were no major differences in the frequency or severity of adverse events between
80		the study vaccination groups, and there were no DS-5670d-related serious adverse
81		events.
82	What	do these findings mean?
82 83	What •	do these findings mean? DS-5670d was immunogenically non-inferior to BNT162b2, which has already been
	What •	
83	What •	DS-5670d was immunogenically non-inferior to BNT162b2, which has already been
83 84	What •	DS-5670d was immunogenically non-inferior to BNT162b2, which has already been widely administered in Japan.
83 84 85	What • •	DS-5670d was immunogenically non-inferior to BNT162b2, which has already been widely administered in Japan. There were no new critical safety concerns associated with DS-5670d, suggesting that it
83 84 85 86	What • •	DS-5670d was immunogenically non-inferior to BNT162b2, which has already been widely administered in Japan. There were no new critical safety concerns associated with DS-5670d, suggesting that it could be a useful SARS-CoV-2 vaccine option.
83 84 85 86 87	What •	DS-5670d was immunogenically non-inferior to BNT162b2, which has already been widely administered in Japan. There were no new critical safety concerns associated with DS-5670d, suggesting that it could be a useful SARS-CoV-2 vaccine option. Taken together, the results from this study of DS-5670d and those from previous studies
83 84 85 86 87 88	What • •	DS-5670d was immunogenically non-inferior to BNT162b2, which has already been widely administered in Japan. There were no new critical safety concerns associated with DS-5670d, suggesting that it could be a useful SARS-CoV-2 vaccine option. Taken together, the results from this study of DS-5670d and those from previous studies evaluating other compositions of DS-5670, i.e., those containing antigens from different
83 84 85 86 87 88 89	What •	DS-5670d was immunogenically non-inferior to BNT162b2, which has already been widely administered in Japan. There were no new critical safety concerns associated with DS-5670d, suggesting that it could be a useful SARS-CoV-2 vaccine option. Taken together, the results from this study of DS-5670d and those from previous studies evaluating other compositions of DS-5670, i.e., those containing antigens from different strains of SARS-CoV-2, provide corroborating evidence that the DS-5670 vaccine

92

It is made available under a CC-BY 4.0 International license .

93 Introduction

94 Although coronavirus disease 2019 (COVID-19) no longer constitutes a global emergency, it 95 remains an ongoing threat to public health [1]. The emergence of novel escape variants of 96 severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), plus waning protective 97 immunity over time, has led to a continuous need for the development, testing and authorization 98 of updated vaccine compositions [2, 3]. The initial roll-out of primary vaccination with 99 monovalent messenger ribonucleic acid (mRNA)-based vaccines such as BNT162b2 100 (Comirnaty, Pfizer-BioNTech) and mRNA-1273 (Spikevax, Moderna) targeting the original 101 Wuhan strain of SARS-CoV-2 [4] was initially followed by boosters with the same monovalent 102 composition, and then by bivalent boosters targeting both the original strain and omicron BA.4-5 103 [5, 6]. Immunization programs against COVID-19 have now moved away from emergency use 104 towards seasonal vaccination, to boost protective immune responses against emerging variants 105 of SARS-CoV-2 [1, 7]. In addition, a single-dose regimen is now recommended for most 106 recipients, as either a primary or booster vaccination [8, 9]. For the 2023/24 season, monovalent 107 vaccine compositions containing an antigen from the omicron XBB.1.5 strain were authorized 108 [10], while for 2024/25, vaccines containing an antigen from the JN.1 lineage have been 109 recommended [11, 12].

110 DS-5670 is a vaccine platform formulation based on mRNA encapsulated in lipid 111 nanoparticles (LNP-mRNA) [13], which can be applied to compositions containing antigens 112 derived from different strains of SARS-CoV-2. To date, several different compositions of DS-113 5670, either monovalent or bivalent, have been clinically evaluated. DS-5670a, a monovalent 114 vaccine containing an antigen from the original strain, demonstrated a clinically acceptable 115 safety profile and favorable immune responses in adults [14], and was authorized in Japan for 116 use as a booster vaccination. DS-5670a/b, a bivalent vaccine containing antigens from both the 117 original strain and from omicron BA.4-5, was shown to be well-tolerated, induced broad

It is made available under a CC-BY 4.0 International license .

neutralization activity across omicron sub-lineages, and was immunogenetically non-inferior to
the bivalent composition of BNT162b2 containing corresponding original and omicron BA.4-5
antigens when administered as a booster vaccination in adults (Daiichi Sankyo Co., Ltd.; data
on file). DS-5670a/b also had a manageable safety profile and showed non-inferior
immunogenicity to bivalent BNT162b2 when administered as a booster to children aged 5–11
years [15].

In November 2023, a monovalent DS-5670 vaccine containing an antigen derived from omicron XBB.1.5 (DS-5670d; Daichirona[®], Daiichi Sankyo Co., Ltd.) was approved by the Japanese Ministry for Health, Labour and Welfare as a booster COVID-19 vaccination [16], and it was launched in December as part of the Japanese immunization program for the 2023/24 season. Herein, we report data from a phase 3 non-inferiority study conducted in adults and children aged \geq 12 years which aimed to evaluate the safety and immunogenicity of a single dose of DS-5670d in those with or without history of prior infection and/or vaccination.

131

132 Methods

133 Participants

134 This study included adults and children aged ≥12 years enrolled from 15 sites across Japan (S1 135 **Table**). Written informed consent was obtained from each participant or their legal 136 representative prior to initiation of study procedures. Eligible participants were stratified into 4 137 subpopulations: (A) those with a history of both SARS-CoV-2 infection and COVID-19 138 vaccination, (B) those with a history of SARS-CoV-2 infection but without a history of COVID-19 139 vaccination, (C) those without a history of SARS-CoV-2 infection but with a history of COVID-19 140 vaccination, or (D) those without any history of SARS-CoV-2 infection or COVID-19 vaccination 141 prior to the date of informed consent. Prior infection was defined as a positive test result for

It is made available under a CC-BY 4.0 International license .

SARS-CoV-2 (either a reverse transcription-polymerase chain reaction test, other nucleic acid
detection test, or SARS-CoV-2 antigen test), or a diagnosis of COVID-19.

144 Key exclusion criteria were the presence of serious cardiovascular, renal, hepatic, blood, 145 neuropsychiatric or developmental disorder, thrombocytopenia, or coagulopathy; history of 146 vaccine-related seizures or epilepsy, or history of anaphylaxis or severe allergy due to 147 administration of food, drugs, cosmetics or vaccines; current or prior history of myocarditis or 148 pericarditis; or a previous diagnosis of immunodeficiency or a close relative with congenital 149 immunodeficiency. Persons who had tested positive for SARS-CoV-2 infection or were 150 diagnosed with COVID-19within 3 months before the date of informed consent, or had 151 symptoms suggestive of SARS-CoV-2 infection at the time of informed consent, or who had a 152 positive SARS-COV-2 test at the time of eligibility evaluation were also ineligible for 153 participation.

154

155 Study design, treatments, and blinding

This was a phase 3 randomized, active-comparator, observer-blind, non-inferiority study registered with the Japan Registry of Clinical Trials with the identifier jRCT2031230424. The study was conducted in accordance with the Declaration of Helsinki, Good Clinical Practice guidelines, and all national and regional ordinance, and was approved by the relevant ethical committees at each study site.

The study design is shown in **Fig. 1A**. Participants were divided into subpopulations A–D according to their prior infection/vaccination status. The members of each subpopulation were then randomly assigned in a 1:1 ratio to receive either DS-5670d (60 µg of mRNA) or monovalent BNT162b2 (containing an antigen from omicron XBB.1.5, 30 µg of mRNA). The comparator BNT162b2 vaccine was supplied by the Japanese government to be used as the

It is made available under a CC-BY 4.0 International license .


study control. Random assignment was the responsibility of an independent statistician, and vaccines were dispensed and administered intramuscularly into the deltoid region of the upper arm by unblinded site personnel on day 1. Investigators were blinded to treatment, and uploaded participant data via an interactive web response system. Participants and their legal representatives, the study monitor and members of the study advisory board, sponsor and collaborators, and personnel performing antibody titer determination were also blinded to vaccine assignment.

173

174 Fig. 1. (A) Study design and (B) CONSORT flow diagram of participant disposition


175 through the study.

176 **A**



It is made available under a CC-BY 4.0 International license .

179 **B**



180

^aThe efficacy FAS and safety analysis sets were identical. ^bIncluded 147 (37.4%) in subpopulation A; 67 (17.0%) in subpopulation B; 163 (41.5%) in subpopulation C, and 16 (4.1%) in subpopulation D. ^cIncluded 139 (36.2%) in subpopulation A; 66 (17.2%) in subpopulation B; 167 (43.5%) in subpopulation C, and 12 (3.1%) in subpopulation D. ^dCombined ABCD subpopulation. FAS, full analysis set; PPS, per protocol set; R, random assignment.

It is made available under a CC-BY 4.0 International license .

181

The first participant was enrolled on 9 January 2024, the initial observation period lasted for 4 weeks post-vaccination, and the follow-up period was planned to continue up to 26 weeks post-vaccination. In the current manuscript, we report the results up to 4 weeks post-

185 vaccination.

186

187 Assessments and outcomes

The study objective was to verify the non-inferiority of DS-5670d to BNT162b2 in terms ofimmunogenicity, and to evaluate safety.

190 A sequential procedure was followed for the immunogenicity analyses. First, non-191 inferiority was tested for the combined ABC subpopulations; only if non-inferiority was confirmed 192 was testing continued for the combined ABCD subpopulation. The primary efficacy endpoint 193 was geometric mean titer (GMT) of blood neutralizing activity against SARS-CoV-2 (omicron 194 variant XBB.1.5) and seroresponse rate at day 29 (4 weeks) after study vaccine administration 195 in participants with any history of SARS-CoV-2 infection and/or vaccination (the combined ABC 196 subpopulation). The key secondary efficacy endpoint was blood neutralizing activity GMT and 197 seroresponse rate at day 29 after study vaccination in all study participants regardless of 198 infection or vaccination history (the combined ABCD subpopulation). The incidence of COVID-199 19 (confirmed by the investigator based on a positive SARS-CoV-2 infection test plus any 200 COVID-19 symptoms) up to day 29 after study vaccination was also evaluated.

201 Safety endpoints included the occurrence of solicited adverse events (AEs), unsolicited 202 AEs, serious AEs (SAEs), and clinically relevant changes in laboratory values. AEs were coded 203 using the Medical Dictionary for Regulatory Activities version 26.1. Health status was recorded 204 in an electronic diary by participants or their representative. Solicited AEs (injection site events

It is made available under a CC-BY 4.0 International license .

[redness, swelling, induration, pain, warmth, and pruritus] and systemic events [fever, malaise,
headache, rash, and myalgia]) were collected up to day 8 post-administration, and unsolicited

AEs and SAEs up to day 29. Laboratory tests were performed pre-vaccination and at day 29

208 post-vaccination.

209

210 Statistical analysis

211 To confirm non-inferiority of DS-5670d versus BNT162b2 at day 29, the lower limit of the two-212 sided 95% confidence interval (CI) of the GMT ratio was required to be above the non-inferiority 213 margin of 0.67, and the lower limit of the two-sided 95% CI for the difference in the 214 seroresponse rate was required to exceed -10% in favor of DS-5670d. Based on this, plus 215 taking into account anticipated dropout rates, the number of participants in the combined ABC 216 subpopulations required to power the immunogenicity non-inferiority comparison was 690 (of 217 whom 345 would receive DS-5670d and 345 would receive BNT162b2). Among these, 100 218 participants (50 per vaccine group) were required to be vaccine-naïve (i.e., included in 219 subpopulation B). No sample size requirement or limitation was set for subpopulation D as the 220 number of eligible participants for this group (no prior infection, no prior vaccination) was 221 considered likely to be small.

222 Immunogenicity analyses were conducted based on the treatment group to which each 223 participant was assigned; the primary analysis population was the immunogenicity-evaluable 224 per protocol set (PPS), which included participants who received a dose of study drug, had a 225 pre-administration and at least one post-administration immunogenicity measurement, and had 226 no protocol violations that could affect the immunogenicity evaluations. Safety analyses were 227 conducted based on the study drug that was actually administered. Unsolicited AEs were 228 evaluated using the safety analysis set, which included all participants who received at least one 229 dose of study drug; solicited AEs were evaluated in the solicited safety analysis set, which

It is made available under a CC-BY 4.0 International license .

included all participants in the safety analysis set for whom information on the occurrence of atleast one solicited AE was available.

232 Baseline participant characteristics were recorded descriptively as number (%), mean 233 (standard deviation [SD]), or median (range). For the calculation of adjusted GMT (and two-234 sided 95% CI), a linear model was applied with common log transformed neutralizing titers as 235 the dependent variable, the study vaccine group as the independent variable, and the common 236 log transformed baseline titer and the categories of subpopulation as covariates. For the 237 adjusted seroresponse rate, the between-group difference (and two-sided 95% CI) was 238 calculated. The Mantel-Haenszel method was applied, and subpopulation was included as a 239 stratum. The COVID-19 incidence rate was calculated using the PPS as the number of cases 240 per 1000 person-years. Solicited AEs were recorded in an electronic diary by each participant or 241 their legal representative; the presence or absence of solicited AEs and their severity were 242 recorded up to 8 days post-vaccine administration, and any other (unsolicited) AEs were 243 recorded up to day 29. The number (%) of participants with events were calculated according to 244 the respective analysis set and tabulated. All statistical calculations were performed using SAS 245 software version 9.4 or later (SAS Institute, Inc., Cary, NC, USA).

246

247 **Results**

248 **Population**

A total of 779 participants were enrolled into the study, of whom 394 were assigned to receive
DS-5670d and 385 to receive BNT162b2 omicron XBB.1.5. The disposition and analysis
populations are presented in Fig. 1B. One participant in each group did not receive study
vaccination, so the safety analysis set included 393 participants in the DS-5670d group and 384

It is made available under a CC-BY 4.0 International license .

253	in the BNT162b2 group. Overall, the safety analysis set included 286 participants in
254	subpopulation A, 133 in subpopulation B, 330 in subpopulation C, and 28 in subpopulation D.
255	After exclusions due to major protocol deviations and lack of immunogenicity data, the
256	immunogenicity-evaluable PPS (combined subpopulations ABCD) included 378 participants in
257	the DS-5670d group and 375 in the BNT162b2 group. For the primary efficacy endpoint, the 28
258	participants in subpopulation D were excluded; thus, the immunogenicity-evaluable ABC
259	subpopulation comprised 362 in the DS-5670d group and 363 in the BNT162b2 group.
260	The demographics and baseline characteristics of participants are described in Table 1 .
261	The median age of participants was 46.0 years (range 12–90 years), with the majority aged
262	between 18–65 years (644/777, 82.9%). Slightly more than half of participants were male
263	(425/777, 54.7%), and had a history of SARS-CoV-2 infection (419/777, 53.9%). Many
264	participants had received prior vaccination (616/777, 79.3%), with monovalent (original strain)
265	vaccines in 313 (40.3%) of participants and bivalent (original strain/omicronBA.4-5) vaccines in
266	275 (35.4%). Characteristics were generally similar across the study vaccine groups, and there
267	were no notable differences between the safety analysis set and the immunogenicity-evaluable
268	PPS.

269

270 Table 1. Baseline demographics and clinical characteristics (safety analysis set).

	DS-5670d	BNT162b2	All participants
	(<i>n</i> = 393)	(<i>n</i> = 384)	(<i>N</i> = 777)
Age (years)			
Median (range)	47.0 (12, 90)	45.5 (12, 77)	46.0 (12, 90)
12–17	35 (8.9)	29 (7.6)	64 (8.2)
18–65	320 (81/4)	324 (84.4)	644 (82.9)

It is made available under a CC-BY 4.0 International license .

≥65	38 (9.7)	31 (8.1)	69 (8.9)
Male sex	214 (54.5)	211 (54.9)	425 (54.7)
Weight (kg), median (range)	62.2 (31, 127)	62.4 (35, 132)	62.4 (31, 132)
Height (cm), median (range)	165.2 (140, 185)	164.1 (147, 190)	164.6 (140, 190)
History of SARS-CoV-2 infection	214 (54.5)	205 (53.4)	419 (53.9)
Self-reported prior infection	181 (46.1)	171 (44.5)	352 (45.3)
Positive antibody test ^a	91 (23.2)	67 (17.4)	158 (20.3)
History of COVID-19 vaccination	310 (78.9)	306 (79.7)	616 (79.3)
Original strain	158 (40.2)	155 (40.4)	313 (40.3)
Original/omicron bivalent	141 (35.9)	134 (34.9)	275 (35.4)
Omicron strain XBB.1.5	11 (2.8)	17 (4.4)	28 (3.6)
Interval from last vaccination (months)			
Median (range)	15.7 (3, 34)	15.4 (3, 30)	15.6 (3, 34)
3–11	48 (12.2)	48 (12.5)	96 (12.4)
≥12	262 (66.7)	257 (66.9)	519 (66.8)
Subpopulation			
A	147 (37.4)	139 (36.2)	286 (36.8)
В	67 (17.0)	66 (17.2)	133 (17.1)
С	163 (41.5)	167 (43.5)	330 (42.5)
D	16 (4.1)	12 (3.1)	28 (3.6)

Both DS-5670d and BNT162b2 were monovalent vaccines against omicron XBB.1.5. Data are reported as *n* (%) unless otherwise stated. All participants (100%) were of Asian race. ^aN-antibody positivity was centrally confirmed by an immunochromatographic test kit (Rapidfields S+N IgG [RF-NC003]; Kurabo Industries Ltd., Osaka, Japan) on day 1 prior to study vaccination. COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome-coronavirus-2.

It is made available under a CC-BY 4.0 International license .


271

272 Immunogenicity/efficacy

- 273 In the primary analysis (combined ABC subpopulations), the adjusted GMT ratio of DS-5670d to
- 274 BNT162b2 was 1.218 (95% CI, 1.059, 1.401). Seroresponse rates were 87.3% in the DS-5670d
- group and 82.9% in the BNT162b2 group; the adjusted difference was 4.5% (95% CI, -0.70,
- 9.71). Both of these results exceeded the prespecified non-inferiority margins (**Table 2**), and the
- study met the primary endpoint.
- 278
- Table 2. Comparison of neutralizing activities against SARS-CoV-2 (omicron XBB.1.5.6) at
- 280 day 29.

	DS-5670d	BNT162b2
Primary analysis (immunogenicity-	N = 362	N = 363
evaluable ABC subpopulation)		
Adjusted GMT (95% CI) ^a	1691.877	1388.927
	(1527.122, 1874.405)	(1253.021, 1539.573)
Adjusted GMT ratio (95% CI) ^a	1.218 (1.059, 1.401)	
Non-inferiority criterion: Met ^b	0.5 <u>0.67</u> 1	
Seroresponse rate (95% CI) ^c	87.3 (83.42, 90.54)	82.9 (78.65, 86.65)
Adjusted difference (95% CI) ^d	4.5 (-0.7	70, 9.71)

It is made available under a CC-BY 4.0 International license .



^aThe adjusted GMT/GMT ratio (DS-5670d vs. BNT162b2 omicron XBB.1.5) and 95% CI were calculated based on an analysis of covariance model with the change of the common log transformed titers as the explained variable, the study drug administration group as the exploratory variable, the common log transformed baseline titers, and the categories of sub-population as the covariates. ^bNon-inferiority criterion for GMT ratio: the lower limit of the 95% CI was required to exceed 0.67. ^cThe 95% CI was calculated based on the Clopper Pearson exact method. ^dThe seroresponse rate adjusted


It is made available under a CC-BY 4.0 International license .

difference (DS-5670d – BNT162b2 omicron XBB.1.5) was calculated using the Mantel-Haenszel method and the 95% CI was calculated based on the stratified Newcombe-Wilson score method (where the strata were the categories of sub-population, i.e., A, B, C, D). eNon-inferiority criterion for difference in seroresponse: the lower limit of the 95% CI of was required to exceed –10%. CI, confidence interval; GMT, geometric mean titer; SARS-CoV-2, severe acute respiratory syndrome-coronavirus-2.

281	
282	In the secondary analysis (combined ABCD subpopulations), the adjusted GMT ratio
283	was 1.185 (95% CI, 1.025, 1.371), and the adjusted difference in seroresponse rate was 3.7%
284	(95% CI, -1.39, 8.87). Again, both results exceeded the prespecified non-inferiority margins
285	(Table 2).
286	An analysis of blood neutralizing activity and seroresponse according to key subgroups
287	(age group, sex, and subpopulation) is shown in Fig. 2. The GMT ratio tended to favor DS-
288	5670d in all patients with a history of vaccination, and also in those with infection history but
289	without a history of vaccination.
290	
291	Fig. 2. Forest plot of immunogenicity against SARS-CoV-2 (omicron XBB.1.5.6) at day 29
292	by subgroup for (A) observed GMT ratio of blood neutralizing activity ^a and (B)
293	seroresponse rate ^b (immunogenicity-evaluable PPS).
294	Α

295


It is made available under a CC-BY 4.0 International license .



296

297

В




It is made available under a CC-BY 4.0 International license .

^aThe observed GMT ratio (DS-5670d vs. BNT162b2 omicron XBB.1.5) and 95% CI were calculated based on the Student's distribution of the mean difference in the log-transformed values then back transformed to the original scale for presentation. ^bThe seroresponse rate observed difference (DS-5670d – BNT162b2 omicron XBB.1.5) and 95% CI were calculated based on the Newcombe-Wilson score method. CI, confidence interval; PPS, per protocol set; SARS-CoV-2, severe acute respiratory syndrome-coronavirus-2.

299
300
301 The incidence rate of COVID-19 to day 29 after study vaccination is presented in Fig. 3.
302 Both study vaccines appeared to be effective in preventing the onset of COVID-19 during this
303 period, with two events reported in the DS-5670d group and three in the BNT162b2 group.

304



305 Fig. 3. Incidence of investigator-confirmed COVID-19 (efficacy-evaluable PPS).

CI, confidence interval; PPS, per protocol set.

It is made available under a CC-BY 4.0 International license .

308

309 Safety

- 310 AEs occurring during the study are summarized in **Table 3**. The majority of participants
- 311 experienced at least one AE, with most AEs judged by the investigator to be vaccine-related.
- 312 There were very few serious AEs across the study vaccine groups; none of the serious AEs
- 313 were judged to be study vaccine-related.
- 314

315 **Table 3. Summary of AEs (safety analysis set).**

	DS-5670d	BNT162b2
	(<i>N</i> = 393)	(<i>N</i> = 384)
Participants with ≥1 solicited AE	365 (92.9)	348 (90.6)
Participants with ≥1 severe solicited AE	20 (5.1)	20 (5.2)
Participants with ≥1 solicited injection site AE	361 (91.9)	339 (88.3)
Participants with ≥1 severe solicited injection site AE	14 (3.6)	12 (3.1)
Participants with ≥1 solicited systemic AE	183 (46.6)	180 (46.9)
Participants with ≥1 severe solicited systemic AE	7 (1.8)	10 (2.6)
Participants with ≥1 unsolicited TEAE	77 (19.6)	74 (19.3)
Participants with ≥1 study vaccine-related unsolicited	32 (8.1)	14 (3.6)
TEAE		
Participants with ≥1 severe unsolicited TEAE	0	0
Participants with ≥1 serious TEAE	0	2 (0.5)
Participants with ≥1 study vaccine-related serious	0	0
TEAE		
Participants with TEAE leading to discontinuation	0	0

It is made available under a CC-BY 4.0 International license .

Participants with fatal TEAE	0	0


Data are shown as n (%). Solicited AEs were collected from the start of the study drug until day 8 after study vaccination. AE, adverse event; TEAE, treatment-emergent adverse event.

316

317

- 318 The majority of solicited AEs were mild or moderate in intensity (**Fig. 4**). The most
- 319 frequently reported solicited injection site AE across both study vaccine groups was mild pain.
- 320 Unsolicited treatment-emergent AEs (all causality and study vaccine-related) are described in
- 321 **S2 Table**. Overall, there were no major differences in the incidence or severity of solicited or
- 322 unsolicited AEs between the study vaccine groups.
- 323
- 324 Fig. 4. Solicited AEs (A) injection site AEs; (B) systemic AEs (safety analysis set).






It is made available under a CC-BY 4.0 International license .



328 **B**



329

AE, adverse event.

330

331

332 Discussion

- 333 In this study, non-inferior immunogenicity of a single dose of monovalent DS-5670d to
- BNT162b2 omicron XBB.1.5 was confirmed in participants aged ≥12 years, regardless of
- infection or vaccination history. Both the primary and secondary efficacy endpoints were met,
- 336 with the non-inferiority criteria being met in both the combined ABC population (with any history
- of prior infection and/or vaccination), and in the overall PPS including participants without any

It is made available under a CC-BY 4.0 International license .

history of prior infection or vaccination. In the combined ABC subpopulation, the adjusted GMT
ratio (DS-5670d vs. BNT162b2) was 1.218 (95% CI, 1.059, 1.401), and the difference in the
seroresponse rate was 4.5 (95% CI, -0.70, 9.71), both of which exceeded the non-inferiority
margin.

342 In the analyses of immunogenicity by key demographic subgroups, there were no 343 apparent differences in GMTs or seroresponse rates according to age group or sex. In addition 344 to providing protective efficacy against severe COVID-19, infection-related death, and long 345 COVID in high risk populations such as older adults [17, 18], recent evidence clearly indicates 346 the benefits of COVID-19 vaccination for children and younger adults in terms of both their 347 mental and physical health [19]. In a country such as Japan, where adults aged ≥65 comprise 348 almost 30% of the population [20], continued vaccine coverage and infection prevention and 349 control measure remain essential to protect at-risk and frail individuals, and sustain medical and 350 social systems [21]. It is also important to achieve good immunogenicity in males, who typically 351 have lower antibody responses to vaccination compared with females [22, 23], and which may 352 impact the attainment of effective population immunity.

353 In the analyses of immunogenicity by subpopulation, the data suggested that even 354 participants without any history of vaccination (subpopulation B) could achieve an adequate 355 immune response with a single dose of DS-5670d. Such data emphasize the universality of DS-356 5670d immunogenicity regardless of prior vaccination history. In terms of participants without 357 any history of infection or vaccination (subpopulation D), DS-5670d appears to be somewhat 358 less immunogenic at first glance, but it is difficult to draw definitive conclusions due to the small 359 number of participants available for evaluation. Overall, however, the participants enrolled in this 360 study are a reasonably accurate reflection of the current real-world situation, where most people 361 have now had a vaccination, or been infected, or both (i.e., comparable to the combined ABC 362 population), and the number of those who have never been infected or vaccinated is dwindling.

It is made available under a CC-BY 4.0 International license .

As such, the confirmation of non-inferiority of DS-5670d among both the ABC population and
the ABCD population suggests that future seasonal DS-5670 vaccines will make a significant
contribution to real-world public health in Japan.

The incidence of COVID-19 up to day 29 after study vaccination was low in both groups. However, the duration of observation was too short, and continued follow-up would be necessary before any inferences regarding the protective effects of DS-5670d can be made.

369 In terms of safety, there were no marked differences between the vaccine groups in the 370 incidence or severity of solicited or unsolicited AEs. In line with results of previous studies 371 evaluating different DS-5670 compositions, the most common solicited injection site AE was 372 injection site pain, with most events being mild or moderate in severity [14, 15]. The most 373 common solicited systemic AE in this study was malaise. This differed from the previously 374 published data for DS-5670a in adults, where myalgia was the most common solicited systemic 375 AE [14]. However, malaise was also the most common solicited systemic AE in studies of DS-376 5670a/b in both adults (Daiichi Sankyo Co., Ltd., data on file) and children [15]. Both injection 377 site pain and malaise (or fatigue) are among the most frequently reported AEs among persons 378 receiving mRNA vaccines against COVID-19, and are not unique to DS-5670 vaccines [24, 25]. 379 There were no serious treatment-emergent unsolicited AEs which were judged to be related to 380 study vaccine.

The main study limitation is the short duration of follow-up, which limits any conclusions relating to the long-term safety of DS-5670d, or the ongoing protection it may offer against COVID-19. In addition, the inclusion of only Asian patients may prevent generalization of the results to other locations and races.

In summary, the results of this phase 3 randomized, active-comparator, observer-blind study demonstrated the immunogenic non-inferiority of a single dose of DS-5670d regardless of history of prior infection or vaccination status and confirmed the clinically acceptable safety

It is made available under a CC-BY 4.0 International license .

- 388 profile. Together with the data from previous DS-5670 clinical studies, these results contribute to
- the growing evidence that this LNP-mRNA vaccine platform technology can be harnessed to
- 390 provide a significant contribution to public health via the production of COVID-19 vaccines in
- 391 future seasons.
- 392

It is made available under a CC-BY 4.0 International license .

- 393 Supporting Information
- 394 **S1 CONSORT Checklist.** Consolidated Standards of Reporting Trials (CONSORT) Checklist.
- 395 (PDF)
- 396 S1 Text. Study protocol. (PDF)
- 397 S1 Table. Listing of study sites and investigators. (PDF)
- 398 S2 Table. Unsolicited AEs occurring in >1 participant in either group (safety analysis set).
- 399 (PDF)
- 400

It is made available under a CC-BY 4.0 International license .

401 Acknowledgments

402 The authors extend their thanks to all the participants and legal representatives who took part in 403 the studies, and to the investigators and staff at the study sites for their support in conducting 404 the study. The authors also thank all members of the clinical study team for valuable advice and 405 support in the performance of this study. Finally, the authors thank Sally-Anne Mitchell, PhD, of 406 McCann Health CMC, for providing medical writing support, which was funded by Daiichi 407 Sankyo Co., Ltd. 408 409 Funding: This study was conducted by Daiichi Sankyo Co., Ltd. (Tokyo, Japan). The work to 410 develop and produce a vaccine against SARS-CoV-2 was funded and supported by the Ministry 411 of Health, Labour and Welfare (MHLW) and Japan Agency for Medical Research and 412 Development (AMED) under Grant Number JP21nf0101625, as part of the initiatives to combat 413 COVID-19. 414 415 Data Availability Statement: The data underlying this report will be made available upon

417

416

reasonable request.

Competing Interests: AK, MH, KI, KF, AO, KT, SS, and FT are employees of Daiichi Sankyo
Co., Ltd.; AO, KT, and SS hold stock in Daiichi Sankyo Co., Ltd. TN reports receiving
remuneration from Daiichi Sankyo Co., KM Biologics Co., Ltd., Meiji Seika Pharma Co., Ltd.,
Mitsubishi Tanabe Pharma Corporation, Moderna, Inc., and Sanofi K.K.

422

It is made available under a CC-BY 4.0 International license .

423 **References**

- 424 1. Ulrichs T, Rolland M, Wu J, Nunes MC, El Guerche-Seblain C, Chit A. Changing
- 425 epidemiology of COVID-19: Potential future impact on vaccines and vaccination
- 426 strategies. Expert Rev Vaccines. 2024;23(1):510-22. doi:
- 427 10.1080/14760584.2024.2346589. PMID: 38656834.
- 428 2. Titball RW, Bernstein DI, Fanget NVJ, Hall RA, Longet S, MacAry PA, et al. Progress with
- 429 COVID vaccine development and implementation. NPJ Vaccines. 2024;9(1):69. doi:

430 10.1038/s41541-024-00867-3. PMID: 38561358; PMCID: PMC10985065.

- Dadras O, SeyedAlinaghi S, Karimi A, Shojaei A, Amiri A, Mahdiabadi S, et al. COVID-19
 vaccines' protection over time and the need for booster doses; A systematic review. Arch
 Acad Emerg Med. 2022;10(1):e53. doi: 10.22037/aaem.v10i1.1582. PMID: 36033989;
 PMCID: PMC9397599.
- 435 4. Teo SP. Review of COVID-19 mRNA vaccines: BNT162b2 and mRNA-1273. Journal of
 436 Pharmacy Practice. 2022;35(6):947-51. doi: 10.1177/08971900211009650. PMID:
 437 33840294.

Goyal L, Zapata M, Ajmera K, Chaurasia P, Pandit R, Pandit T. A Hitchhiker's Guide to
worldwide COVID-19 vaccinations: A detailed review of monovalent and bivalent vaccine
schedules, COVID-19 vaccine side effects, and effectiveness against omicron and delta
variants. Cureus. 2022;14(10):e29837. doi: 10.7759/cureus.29837. PMID: 36204257;
PMCID: PMC9527088.

6. Chatzilena A, Hyams C, Challen R, Marlow R, King J, Adegbite D, et al. Relative vaccine
effectiveness of mRNA COVID-19 boosters in people aged at least 75 years during the
spring-summer (monovalent vaccine) and autumn-winter (bivalent vaccine) booster

It is made available under a CC-BY 4.0 International license .

- 446 campaigns: A prospective test negative case-control study, United Kingdom, 2022. Euro
- 447 Surveill. 2023;28(48):2300173. doi: 10.2807/1560-7917.ES.2023.28.48.2300173. PMID:
- 448 38037728; PMCID: PMC10690860.
- 449 7. Murray CJL, Piot P. The potential future of the COVID-19 pandemic: Will SARS-CoV-2
- 450 become a recurrent seasonal infection? JAMA. 2021;325(13):1249-50. doi:
- 451 10.1001/jama.2021.2828. PMID: 33656519.
- 452 8. US Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes
- 453 changes to simplify use of bivalent mRNA COVID-19 vaccines; 18 April 2023. Available
- 454 from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-
- 455 update-fda-authorizes-changes-simplify-use-bivalent-mrna-covid-19-vaccines.
- 456 9. European Centre for Disease Prevention and Control, European Medicines Agency.
- 457 ECDC-EMA statement on updating COVID-19 vaccines composition for new SARS-CoV-2
- 458 virus variants; 6 June 2023. Available from:
- 459 https://www.ema.europa.eu/system/files/documents/other/ecdc-
- 460 ema_statement_on_updating_covid-19_vaccines_composition_for_new_sars-cov-
- 461 2_virus_variants_en.pdf.
- 462 10. Regan JJ, Moulia DL, Link-Gelles R, Godfrey M, Mak J, Najdowski M, et al. Use of
- 463 updated COVID-19 vaccines 2023-2024 formula for persons aged ≥6 months:
- 464 Recommendations of the Advisory Committee on Immunization Practices United States,
- 465 September 2023. MMWR Morb Mortal Wkly Rep. 2023;72(42):1140-6. doi:
- 466 10.15585/mmwr.mm7242e1. PMID: 37856366; PMCID: PMCPMC10602621.
- 467 11. European Medicines Agency. News: ETF recommends updating COVID-19 vaccines to
- 468 target new JN.1 variant; 30 April 2024. Available from:

It is made available under a CC-BY 4.0 International license .

- 469 https://www.ema.europa.eu/en/news/etf-recommends-updating-covid-19-vaccines-target-
- 470 new-jn1-variant.
- 471 12. US Food and Drug Administration. Updated COVID-19 vaccines for use in the United
- 472 States beginning in Fall 2024; 5 June 2024. Available from: https://www.fda.gov/vaccines-
- 473 blood-biologics/updated-covid-19-vaccines-use-united-states-beginning-fall-2024.
- 474 13. Yabuta M, Takeshita F, Ueno S, Tanaka N, Yano T, Oe K, et al. Development of an
- 475 mRNA vaccine against COVID-19. Trans Regulat Sci. 2021;3(3):118-9. doi:
- 476 10.33611/trs.2021-020.
- 477 14. Toyama K, Eto T, Takazawa K, Shimizu S, Nakayama T, Furihata K, et al. DS-5670a, a
- 478 novel mRNA-encapsulated lipid nanoparticle vaccine against severe acute respiratory
- 479 syndrome coronavirus 2: Results from a phase 2 clinical study. Vaccine.
- 480 2023;41(38):5525-34. doi: 10.1016/j.vaccine.2023.07.012. PMID: 37586958.
- 481 15. Suzuki R, Suda M, Ishida K, Furihata K, Ota A, Takahashii K, et al. Booster vaccination
- 482 using bivalent DS-5670a/b is safe and immunogenic against SARS-CoV-2 variants in
- 483 children aged 5-11 years: A phase 2/3, randomized, active-controlled study. Front
- 484 Immunol. 2024;15:doi:10.3389/fimmu.2024.1445459. doi: 10.3389/fimmu.2024.1445459.
- 485 16. Daiichi-Sankyo. Press release: Daichirona® for intramuscular injection for booster
- 486 vaccination approved in Japan as omicron XBB.1.5-adapted monovalent mRNA vaccine
- 487 against COVID-19; 28 November 2023. Available from:
- 488 https://www.daiichisankyo.com/files/news/pressrelease/pdf/202311/20231128_E.pdf.
- 489 17. Xu K, Wang Z, Qin M, Gao Y, Luo N, Xie W, et al. A systematic review and meta-analysis
 490 of the effectiveness and safety of COVID-19 vaccination in older adults. Front Immunol.

It is made available under a CC-BY 4.0 International license .

491 2023;14:1113156. doi: 10.3389/fimmu.2023.1113156. PMID: 36936964; PMCID:


492 PMC10020204.

- 493 18. Mimura W, Ishiguro C, Terada-Hirashima J, Matsunaga N, Sato S, Kawazoe Y, et al.
- 494 Effectiveness of BNT162b2 against infection, symptomatic infection, and hospitalization
- among older adults aged ≥65 years during the delta variant predominance in Japan: The
- 496 VENUS study. J Epidemiol. 2024;34(6):278-85. doi: 10.2188/jea.JE20230106. PMID:
- 497 37743530; PMCID: PMC11078592.
- 498 19. McGrew S, Taylor HA. Adolescents, parents, and COVID-19 vaccination Who should
- 499 decide? N Engl J Med. 2022;386(2):e2. doi: 10.1056/NEJMp2116771. PMID: 34965336.
- Japan Ministry of Internal Affairs and Communications. Statistics Topic No. 138: Japan's
 elderly seen from statistics (Respect for the Aged Day); 18 September 2023. Available
 from: https://www.stat.go.jp/data/topics/pdf/topi138_01.pdf.
- 503 21. Hasegawa T, Hirata K, Matsumoto K. Lessons from the COVID-19 pandemic: Strategies
 504 and challenges for an aging society in Japan. Public Administration and Policy: An Asia505 Pacific Journal. 2023;26(1):21-35. doi: 10.1108/PAP-10-2022-0123.
- 506 22. Flanagan KL, Fink AL, Plebanski M, Klein SL. Sex and gender differences in the
 507 outcomes of vaccination over the life course. Annu Rev Cell Dev Biol. 2017;33:577-99.
 508 doi: 10.1146/annurev-cellbio-100616-060718. PMID: 28992436.
- 509 23. Ciarambino T, Barbagelata E, Corbi G, Ambrosino I, Politi C, Lavalle F, et al. Gender
- 510 differences in vaccine therapy: Where are we in COVID-19 pandemic? Monaldi Arch
- 511 Chest Dis. 2021;91(4):1669. doi: 10.4081/monaldi.2021.1669. PMID: 33840183.

It is made available under a CC-BY 4.0 International license .

- 512 24. Kouhpayeh H, Ansari H. Adverse events following COVID-19 vaccination: A systematic
- 513 review and meta-analysis. Int Immunopharmacol. 2022;109:108906. Epub 20220530. doi:
- 514 10.1016/j.intimp.2022.108906. PMID: 35671640; PMCID: PMC9148928.
- 515 25. Rabail R, Ahmed W, Ilyas M, Rajoka MSR, Hassoun A, Khalid AR, et al. The side effects
- 516 and adverse clinical cases reported after COVID-19 immunization. Vaccines (Basel).
- 517 2022;10(4):488. doi: 10.3390/vaccines10040488. PMID: 35455237; PMCID:
- 518 PMC9031559.

Fig. 1A






Fig. 1B

Fig. 2A




Fig. 2B

Subgroup	Participants, n (%)	Difference in seroresponse rate (95% CI) DS-5670d vs. BNT162b2 (omicron XBB.1.5)	Difference in seroresponse ratio (95% CI)
Age Group			
12–17 years	63 (8.4)	⊢ − −−−	-0.9 (-18.4, 17.8)
18-64 years	621 (82.5)	H=-1	3.1 (-2.4, 8.7)
≥65 years	69 (9.2)	⊢ ↓ ↓ ↓	13.2 (-6.3, 32.7)
Sex			
Male	414 (55.0)	⊢	4.0 (-2.9, 10.9)
Female	339 (45.0)	⊢↓	3.0 (-4.6, 10.7)
Subpopulation			
Subpopulation A	275 (36.5)	⊢ •−−1	10.5 (1.0, 19.9)
Subpopulation B	129 (17.1)	⊢ ● <u></u>	-6.1 (-16.9, 4.5)
Subpopulation C	321 (42.6)	⊢ ● ⊸(3.6 (-3.8, 11.0)
Subpopulation D	28 (3.7)	⊢	-16.7 (-42.1, 14.2)
	-60%	-40% -20% 0 20% 40%	60%
		Favors BNT162b2 Favors DS-5670d	

Fig. 3




Fig. 4A




Fig. 4B




Table 2

